STUDI PENGGUNAAN CLOPIDOGREL PADA PASIEN PENYAKIT JANTUNG KORONER (Penelitian dilakukan di RSI Aisyiyah Malang)

Background : In 2019, cardiovascular disease caused more than 17.9 million deaths. Coronary Heart Disease is caused by plaque buildup in the coronary arteries causing blood flow to be blocked forming atherosclerosis (thrombus). Clopidogrel as an antiplatelet therapy is the mainstay pharmacological treatment to reduce platelet aggregation and prevent thrombus formation.
Objective : To determine the pattern of clopidogrel usage in patients with coronary heart disease, including type, dosage, route, frequency, and duration of administration at RSI Aisyiyah Malang.
Method : This research is observational or non-experimental , namely in the form of a retrospective study with a consecutive sampling method in coronary artery disease patients for the period 1 January to 31 December 2023.
Results and Coclucsions : The most common pattern of Single Therapy Use was Clopidogrel (1x75 mg) po in 22 patients. The most common pattern of Combination Therapy 2 use was Acetosal (1x80 mg) po + Clopidogrel (1x75 mg) po in 52 patients (60%). The use of Combination Therapy 3 used in this study was Acetosal (1x320 mg) po + Clopidogrel (1x300 mg) po + Ticagrelor (1x180 mg) po in 5 patients (56%) . There were a total of 45 switches.